NEW YORK, July 16, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Aeterna Zentaris Inc. (NASDAQ: AEZS), Ariad
Pharmaceuticals Inc. (NASDAQ: ARIA), AVEO Pharmaceuticals Inc.
(NASDAQ: AVEO), Aduro BioTech Inc. (NASDAQ: ADRO), and 22nd Century
Group Inc. (AMEX: XXII). Free research report on Aeterna Zentaris
can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=AEZS On
Wednesday, July 15, 2015, the NASDAQ
Composite ended at 5,098.94, down 0.12%, the Dow Jones Industrial
Average edged 0.02% lower, to finish the day at 18,050.17, and the
S&P 500 closed at 2,107.40, down 0.07%. The losses were broad
based as six out of nine sectors ended the session in negative.
Register for your complimentary reports at the links given below.
On Wednesday, shares in Aeterna Zentaris Inc. recorded a trading
volume of 3.30 million shares, lower than their three months
average volume of 3.96 million shares. The stock ended the day
4.20% lower at $0.23. Aeterna
Zentaris Inc.'s stock has lost 20.05% in the last one month, 64.08%
in the previous three months and 61.98% on YTD basis. The company
is trading below its 50-day and 200-day moving averages by 29.57%
and 62.46%, respectively. Furthermore, shares of Aeterna Zentaris
Inc. have a Relative Strength Index (RSI) of 26.42. Sign up and
read the free notes on AEZS at:
https://www.EquityResearchInstitute.com/reports?keyword=AEZS
Ariad Pharmaceuticals Inc.'s stock declined 1.65%, to close
Wednesday's session at $8.35. The
stock recorded a trading volume of 3.72 million shares, below its
three months average volume of 3.83 million shares. Over the last
one month and the previous three months, Ariad Pharmaceuticals
Inc.'s shares have lost 2.34% and 6.49%, respectively. However, the
stock has gained 21.54% on YTD basis. The company is trading 11.57%
above its 200-day moving average. Furthermore, Ariad
Pharmaceuticals Inc.'s stock has an RSI of 50.19. The complimentary
notes on ARIA can be downloaded in PDF format at:
https://www.EquityResearchInstitute.com/reports?keyword=ARIA
AVEO Pharmaceuticals Inc.'s stock finished Wednesday's session
3.13% lower at $1.55. A total of 0.59
million shares were traded, which was much below its three months
average volume of 3.87 million shares. Over the previous three
months and since the beginning of 2015, AVEO Pharmaceuticals Inc.'s
shares have surged 4.73% and 84.52%, respectively. However, the
stock has lost 23.27% in the last one month. The company's shares
are trading above their 200-day moving average by 20.81%. AVEO
Pharmaceuticals Inc.'s stock has an RSI of 43.82. Register for free
on Equity Research Institute and access the latest research on AVEO
at:
https://www.EquityResearchInstitute.com/reports?keyword=AVEO
On Wednesday, shares in Aduro BioTech Inc. ended the session
0.36% higher at $30.95. The stock
reported a trading volume of 0.14 million shares, below its three
months average volume of 0.55 million shares. Aduro BioTech Inc.'s
shares have declined 14.03% in the last one month, 26.31% in the
previous three months and 26.31% on YTD basis. The company is
trading 3.77% below its 50-day moving average and 5.37% below its
200-day moving average. Moreover, shares of Aduro BioTech Inc. have
an RSI of 44.79. The complete research on ADRO is available for
free at:
https://www.EquityResearchInstitute.com/reports?keyword=ADRO
22nd Century Group Inc.'s stock lost 3.91%, to close the day at
$0.81. The stock recorded a trading
volume of 0.33 million shares, below its three months average
volume of 0.56 million shares. Over the last one month and the past
three months, 22nd Century Group Inc.'s shares have declined 11.95%
and 2.39%, respectively. Furthermore, the stock has lost 50.91%
since the start of this year. The company's shares are trading
18.49% below their 50-day moving average and 41.19% below their
200-day moving average. Additionally, 22nd Century Group Inc. has
an RSI of 37.39. Free in-depth research on XXII is available
at:
https://www.EquityResearchInstitute.com/reports?keyword=XXII
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com